Pfizer stock offers 30% upside with strong non-COVID franchises, margin expansion, and pipeline potential. Click here to read ...

Wondering if Pfizer is a smart buy at today's price? You are not alone, especially as value-focused investors begin to focus on the stock. Pfizer's performance has been mixed lately. Shares dipped ...

If you own or are considering buying pharma laggards Pfizer ( PFE +1.42%), Bristol Myers Squibb ( BMY +0.26%), and Merck ( ...

Pfizer (NYSE: PFE) and Teva Pharmaceutical Industries (NYSE: TEVA) just reported third-quarter earnings that reveal two ...

Pfizer Inc. (NYSE:PFE) is one of the best low volatility large cap stocks to invest in. On November 24, Guggenheim lifted the ...

More than a year after its promised deadline to investors, drugmaker puts alarming results in federal government's "virtual ...

Pfizer acquired a smaller company for $4.9 billion to improve its prospects in the GLP-1 market. The pharmaceutical giant could carve out a small niche for itself in this growing space. Pfizer's ...

Pfizer offers value with a strong dividend, Metsera obesity expansion, PADCEV/Keytruda approval, and an oncology pipeline.

3SBio, a China partner of U.S. drug giant Pfizer, has reached agreements to raise approximately $400 million in a share ...

With all that in mind, if you have $2,000 available to invest that isn't needed for monthly bills, to pay down short-term ...

The GLP-1 agonist at the center of Pfizer’s upfront $4.9 billion buyout of Metsera last week has been tied to 14.1% weight loss at 28 weeks as well as “potentially class-leading tolerability,” ...

The CHMP’s recommendation will be reviewed by the European Commission (EC), which is expected to make its final decision soon. Pfizer and BioNTech have already initiated manufacturing of the ...